These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 9679947)
1. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Lode HN; Reisfeld RA; Handgretinger R; Nicolaou KC; Gaedicke G; Wrasidlo W Cancer Res; 1998 Jul; 58(14):2925-8. PubMed ID: 9679947 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1. Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma]. Li JZ; Jiang M; Xue YC; Zhen YS Yao Xue Xue Bao; 1993; 28(4):260-5. PubMed ID: 8213168 [TBL] [Abstract][Full Text] [Related]
6. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156 [TBL] [Abstract][Full Text] [Related]
7. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546 [TBL] [Abstract][Full Text] [Related]
8. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105 [TBL] [Abstract][Full Text] [Related]
9. Suppression of primary tumor growth in a mouse model of human neuroblastoma. Rowe DH; Huang J; Li J; Manley C; O'Toole KM; Stolar CJ; Yamashiro DJ; Kandel JJ J Pediatr Surg; 2000 Jun; 35(6):977-81. PubMed ID: 10873048 [TBL] [Abstract][Full Text] [Related]
10. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Cheung NK; Modak S Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541 [TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice]. Liu XJ; Dai Y; Shang Y; Li Y; Zhen YS Ai Zheng; 2005 Jun; 24(6):641-5. PubMed ID: 15946470 [TBL] [Abstract][Full Text] [Related]
12. Disialoganglioside directed immunotherapy of neuroblastoma. Modak S; Cheung NK Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560 [TBL] [Abstract][Full Text] [Related]
13. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088 [TBL] [Abstract][Full Text] [Related]
14. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Fest S; Huebener N; Weixler S; Bleeke M; Zeng Y; Strandsby A; Volkmer-Engert R; Landgraf C; Gaedicke G; Riemer AB; Michalsky E; Jaeger IS; Preissner R; Förster-Wald E; Jensen-Jarolim E; Lode HN Cancer Res; 2006 Nov; 66(21):10567-75. PubMed ID: 17079481 [TBL] [Abstract][Full Text] [Related]
15. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447 [TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule]. Liu XY; Zhen YS Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099 [TBL] [Abstract][Full Text] [Related]
18. Mylotarg approved for patients with CD33+ acute myeloid leukemia. Sorokin P Clin J Oncol Nurs; 2000; 4(6):279-80. PubMed ID: 11899326 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235 [TBL] [Abstract][Full Text] [Related]